• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » COVID Variants Delaying Recruiting in Reopening Trials

COVID Variants Delaying Recruiting in Reopening Trials

February 15, 2021

Trials disrupted by the first wave of the COVID-19 pandemic in 2020 are continuing to reopen, but the emergence of two more contagious variants of the SARS-CoV-2 virus resulted in a drop in the rate of recruitment in January, according to data analysis firm GlobalData.

More than 900 disrupted trials had resumed as of Jan. 25, with 79.9 percent of them currently recruiting participants. More than 12 percent have completed recruitment and 0.5 percent of trials have yet to start recruiting participants.

And while the number of trials resuming activity has been increasing, the period between Dec. 23, 2020, and Jan. 25, 2021, saw a decline in the number of trials actively recruiting to 71.9 percent from 74.6 percent in the previous months. Global Data attributes the drop to increased restrictive measures countries have put in place as the new UK and South Africa variants emerged.

The U.S. has the highest number of resumed trials at 87.5 percent, Global Data said, followed by the UK (10.8 percent), Spain (9 percent), France (8.8 percent) and Germany (8.1 percent).

The number of trials completed increased to 12.8 in January from 10.6 percent in 2020.

COVID-19
  • Related Directories

    Veklury (remdesivir)

    Pfizer-BioNtech COVID-19 Vaccine

    Moderna COVID-19 Vaccine (mRNA-1273)

Upcoming Events

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • InputinLights-360x240.png

    Seeking Patient Input Early Helps Ensure Minority Participation in Trials

  • Oncology-360x240.png

    Global Oncology Trial Launches Drop Dramatically During Pandemic, Study Shows

  • Qualification-360x240.png

    Sites and Sponsors Streamlining Qualification Efforts with Technology, Process Revisions

  • New Algorithm Tested and Validated by CSDD Highly Predictive of Patient Burden

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing